News
RLMD
2.620
-15.76%
-0.490
Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
NASDAQ · 4d ago
Leerink Partners Keeps Their Buy Rating on Relmada Therapeutics (RLMD)
TipRanks · 4d ago
Relmada Therapeutics Appoints Chief Development Officer for Urology
TipRanks · 4d ago
Weekly Report: what happened at RLMD last week (1109-1113)?
Weekly Report · 4d ago
Press Release: Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Dow Jones · 4d ago
Relmada Therapeutics (RLMD) Gets a Buy from H.C. Wainwright
TipRanks · 11/13 14:39
Piper Sandler Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
TipRanks · 11/13 14:05
Relmada Therapeutics Reports Third-Quarter Results and Business Update
TipRanks · 11/12 21:43
Relmada Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate. Cash and Equivalents $202.1M.
Benzinga · 11/12 21:06
Here are the major earnings after the close Thursday
Seeking Alpha · 11/12 15:00
Weekly Report: what happened at RLMD last week (1102-1106)?
Weekly Report · 11/09 10:04
Weekly Report: what happened at RLMD last week (1026-1030)?
Weekly Report · 11/02 10:04
Weekly Report: what happened at RLMD last week (1019-1023)?
Weekly Report · 10/26 10:03
Weekly Report: what happened at RLMD last week (1012-1016)?
Weekly Report · 10/19 10:03
Weekly Report: what happened at RLMD last week (1005-1009)?
Weekly Report · 10/12 10:08
Weekly Report: what happened at RLMD last week (0928-1002)?
Weekly Report · 10/05 10:07
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/29 21:06
Weekly Report: what happened at RLMD last week (0921-0925)?
Weekly Report · 09/28 10:03
Weekly Report: what happened at RLMD last week (0914-0918)?
Weekly Report · 09/21 10:03
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement
Seeking Alpha · 09/14 18:50
More
Webull provides a variety of real-time RLMD stock news. You can receive the latest news about Relmada Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.